Suchergebnisse
Cardiogenic shock retains its high mortality of 50-70% within the first 30 days after diagnosis, despite the progress in intensive care and circulatory support using vasopressors, inotropes and mechanical circulatory assist devices.
4TEEN4 Pharmaceuticals is built on science, innovation, and dedication, where you can use your enthusiasm in changing patients’ lives and creating impact. We are a fast-growing, small-medium enterprise (SME) that grants our employees the ability to grow and shape their career pathways by developing an agile approach.
Discover how 4TEEN4 Pharmaceuticals' innovation, Procizumab, a humanized monoclonal antibody targeting DPP3, offers new hope by improving outcomes and guiding therapy escalation in acute critical disease entities.
A breakthrough, first in class asset with pre-clinical proof of concept to restore cardiac function and prevent death due to Cardiogenic Shock. 4TEEN4 Pharmaceuticals pioneers precision medicine to restore cardiac and vascular function and to prevent fatalities in critical acute cardiovascular complications with limited or no effective ...
10. Dez. 2019 · Der Wirkstoff Procizumab blockiert die cDPP3 und bietet damit einen alternativen, neuartigen Ansatz zur Verringerung der Sterblichkeit bei Patienten mit akutem Herz-Kreislauf-Versagen unter intensivmedizinischer Versorgung. 4TEEN4 wird nun die Wirksamkeit von Procizumab in klinisch relevanten Modellen für kardiogenen Schock nachweisen.
Der Fokus der 4TEEN4 Pharmaceuticals sind Patienten mit Erkrankungen, die mit massivem Zelltod und damit zusammenhängend einer unkontrollierten Freisetzung von Dipeptidylpeptidase 3 (DPP3) in die Blutbahn verbunden sind.
1. Dez. 2021 · The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab.
